QURE logo

Uniqure NV (QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for th...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
QURE
ISIN Code
NL0010696654
Currency
US Dollar (USD)
IPO Date
2007-06-20

Contact Information

Company Address
Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
Contact Phone
31 20 240 6000
Company Website
https://www.uniqure.com
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$-999,999.99
Return on Assets (TTM)
-15.72%
EBITDA
$-999,999.99
Revenue (TTM)
$999,999.99